word,tfidf
analysis,0.2340145823998447
treatment,0.2069181570693364
95,0.1765455297816443
analyses,0.1703509497893059
test,0.15518861780200227
arms,0.15176720981229075
estimated,0.14247533982378316
arm,0.14040874943990683
endpoints,0.13512146141691309
primary,0.13055550386517653
response,0.12809219247149395
bayesian,0.12596690312389716
probability,0.12316556968412881
interquartile,0.12024509257526181
estimator,0.12024509257526181
interim,0.11769701985442955
endpoint,0.1158183955002112
characteristics,0.1158183955002112
randomized,0.1158183955002112
median,0.11546966119690574
rate,0.1133123241093985
competing,0.11099547006947244
compared,0.11030323380972497
intent,0.10775248156101767
efficacy,0.10478807211923871
confidence,0.10174584756368306
described,0.09911327987741436
range,0.09447517734292288
design,0.09291869988507596
exact,0.0924962250578937
ci,0.09178915095938542
statistical,0.09097609670059241
treat,0.08982140988890676
percentages,0.08787141380499901
incidence,0.08548500620253684
summary,0.0838074856585693
set,0.08362682989656836
sided,0.08324660255210434
cohort,0.08047885477360096
kaplan,0.07981665300816124
gray,0.07862179129920964
group,0.07636265320415986
data,0.07636265320415986
risks,0.07582582035775318
model,0.07389934181047728
included,0.07169710197632122
effect,0.07169710197632122
safety,0.07143603041679471
posterior,0.07143603041679471
binomial,0.06998161284660953
computed,0.06814037991572237
sample,0.06814037991572237
events,0.06650940762942956
m12,0.06648253220427906
beta,0.06504308991955317
secondary,0.06404609623574697
means,0.063853322406529
meier,0.063853322406529
models,0.061945799923383976
stage,0.060666778595348726
summarized,0.060122546287630904
tests,0.059484370919618106
informative,0.059484370919618106
intervals,0.059484370919618106
adverse,0.059119473448381823
difference,0.05884850992721478
log,0.05587165710571287
quantitative,0.05587165710571287
categorical,0.05549773503473622
hazard,0.05549773503473622
criteria,0.055151616904862484
event,0.05419285066101667
inclusion,0.05419285066101667
cumulative,0.05265392993487637
counts,0.052394036059619356
presented,0.052394036059619356
risk,0.0517295392673341
linear,0.05087292378184153
significance,0.05087292378184153
cox,0.05087292378184153
week,0.049636455214376235
m6,0.04955663993870718
survival,0.04926622787365152
measures,0.04926622787365152
following,0.04926622787365152
observed,0.04926622787365152
distribution,0.04898712899262668
inference,0.04898712899262668
rank,0.04898712899262668
combination,0.04898712899262668
planned,0.04898712899262668
phase,0.046802916479968946
considered,0.046802916479968946
toxicity,0.046802916479968946
ii,0.046802916479968946
05,0.04645934994253798
disposition,0.04624811252894685
sas,0.04624811252894685
random,0.045488048350296205
general,0.045488048350296205
strategy,0.045488048350296205
methods,0.045488048350296205
end,0.04433960508628637
20,0.04433960508628637
experimental,0.044121293523889986
use,0.044121293523889986
size,0.044121293523889986
16,0.044121293523889986
given,0.044121293523889986
comparison,0.044121293523889986
type,0.044121293523889986
error,0.04389915915448868
censored,0.04389915915448868
analysed,0.04336205994636878
m24,0.04198896770796573
continuous,0.04198896770796573
intolerance,0.04198896770796573
rules,0.04198896770796573
follow,0.041876293692603796
distributions,0.04162330127605217
logrank,0.04162330127605217
criterion,0.04026476995019958
inclusions,0.03990832650408062
pt,0.03848988706563524
observations,0.03716747995403038
stopping,0.03716747995403038
iqr,0.03699849002315748
priors,0.03699849002315748
greater,0.03694967090523864
estimates,0.03591749385367255
org,0.03591749385367255
stop,0.03591749385367255
baseline,0.03584855098816061
similarly,0.034990806423304766
stopped,0.034990806423304766
compare,0.034990806423304766
gvhd,0.03448635951155606
assessed,0.03448635951155606
frequency,0.03309097014291749
received,0.03309097014291749
power,0.032373678770262794
terminal,0.032373678770262794
51,0.032373678770262794
relapse,0.03202304811787349
table,0.030972899961691988
level,0.029559736724190912
post,0.029559736724190912
24,0.029559736724190912
sequential,0.027992645138643815
changes,0.027992645138643815
monotherapy,0.027992645138643815
promising,0.027935828552856434
project,0.027935828552856434
futility,0.027935828552856434
enrolled,0.027875609965522786
setting,0.027875609965522786
w55,0.027875609965522786
unacceptable,0.027875609965522786
proportional,0.02774886751736811
logistic,0.02774886751736811
principle,0.02774886751736811
fisher,0.02774886751736811
packages,0.02774886751736811
population,0.027575808452431242
completed,0.027575808452431242
considering,0.027575808452431242
percentage,0.027575808452431242
factors,0.027575808452431242
total,0.027096425330508336
interval,0.027096425330508336
death,0.027096425330508336
12,0.027096425330508336
required,0.024818227607188117
calculated,0.024818227607188117
100,0.024818227607188117
month,0.024818227607188117
mean,0.024818227607188117
www,0.02477831996935359
maximum,0.02477831996935359
discontinuation,0.02477831996935359
point,0.02477831996935359
includes,0.02463311393682576
main,0.02463311393682576
overall,0.02463311393682576
10,0.02463311393682576
software,0.02449356449631334
unless,0.02449356449631334
prognostic,0.02449356449631334
borr,0.02449356449631334
binary,0.02449356449631334
consider,0.02449356449631334
conducted,0.02394499590244837
alpha,0.02394499590244837
observation,0.02394499590244837
compute,0.02394499590244837
adjustment,0.02394499590244837
hazards,0.023124056264473426
nc,0.023124056264473426
estimations,0.023124056264473426
nonparametric,0.023124056264473426
cary,0.023124056264473426
remission,0.022169802543143186
potential,0.022169802543143186
best,0.022169802543143186
randomization,0.022169802543143186
value,0.022169802543143186
transplant,0.022169802543143186
30,0.022169802543143186
treated,0.022169802543143186
25,0.022060646761944993
spartalizumab,0.022060646761944993
2014,0.022060646761944993
normal,0.022060646761944993
free,0.022060646761944993
responses,0.022060646761944993
measured,0.02168102997318439
m3,0.02168102997318439
expected,0.02168102997318439
http,0.02168102997318439
reasons,0.02168102997318439
enrolment,0.02168102997318439
minimal,0.020994483853982865
inferiority,0.020994483853982865
exploratory,0.020994483853982865
w12,0.020994483853982865
w24,0.020994483853982865
administered,0.020994483853982865
threshold,0.020994483853982865
w36,0.020994483853982865
specifically,0.01995416325204031
evaluating,0.01995416325204031
null,0.01995416325204031
permanently,0.01995416325204031
actually,0.01995416325204031
framework,0.01995416325204031
resources,0.01995416325204031
sectional,0.01995416325204031
adjusted,0.01995416325204031
called,0.01995416325204031
quality,0.01970649114946061
treatments,0.01970649114946061
sensitivity,0.01970649114946061
information,0.01970649114946061
disease,0.01970649114946061
groups,0.01970649114946061
complete,0.01970649114946061
acute,0.01970649114946061
ratio,0.01930306591670187
points,0.01930306591670187
historical,0.01930306591670187
evaluated,0.01930306591670187
approach,0.01930306591670187
score,0.01930306591670187
evaluation,0.01930306591670187
occurrence,0.01930306591670187
section,0.01858373997701519
regression,0.01858373997701519
recorded,0.01858373997701519
hypothesis,0.01858373997701519
assuming,0.01849924501157874
hypotheses,0.01849924501157874
differences,0.01849924501157874
conclude,0.01849924501157874
denotes,0.01849924501157874
property,0.01849924501157874
propensity,0.01849924501157874
credible,0.01849924501157874
operating,0.01849924501157874
curves,0.01849924501157874
bayes,0.01849924501157874
dsmb,0.017495403211652383
simons,0.017495403211652383
cross,0.017495403211652383
w16,0.017495403211652383
fixed,0.017495403211652383
w20,0.017495403211652383
necessary,0.017495403211652383
sampling,0.017495403211652383
cost,0.017495403211652383
statistics,0.017495403211652383
w8,0.017495403211652383
w30,0.017495403211652383
estimation,0.017495403211652383
w4,0.017495403211652383
targeted,0.017495403211652383
corresponding,0.017495403211652383
transplantation,0.01724317975577803
count,0.01724317975577803
days,0.01724317975577803
grade,0.01724317975577803
parameters,0.016545485071458744
refer,0.016545485071458744
proportion,0.016545485071458744
80,0.016545485071458744
right,0.016545485071458744
ratios,0.01596333060163225
checked,0.01596333060163225
planning,0.01596333060163225
pcra,0.01596333060163225
natural,0.01596333060163225
journal,0.01596333060163225
corresponds,0.01596333060163225
confounders,0.01596333060163225
bias,0.01596333060163225
designs,0.01596333060163225
superiority,0.01596333060163225
thickness,0.01596333060163225
values,0.015486449980845994
106,0.015486449980845994
discontinued,0.015486449980845994
grfs,0.015486449980845994
respectively,0.015486449980845994
fully,0.015486449980845994
estimate,0.015486449980845994
analyzed,0.015486449980845994
increase,0.014779868362095456
progression,0.014779868362095456
additional,0.014779868362095456
levels,0.014779868362095456
retinal,0.014779868362095456
cell,0.014779868362095456
specific,0.014779868362095456
optimal,0.014779868362095456
duration,0.014779868362095456
early,0.014779868362095456
kg,0.014779868362095456
severity,0.014779868362095456
prevalence,0.013996322569321908
missing,0.013996322569321908
pga,0.013996322569321908
m15,0.013996322569321908
tested,0.013996322569321908
compliance,0.013996322569321908
half,0.013996322569321908
extension,0.013996322569321908
experienced,0.013996322569321908
equal,0.013996322569321908
sequentially,0.013996322569321908
conjugate,0.013996322569321908
questions,0.013996322569321908
saes,0.013996322569321908
proportions,0.013996322569321908
depending,0.013996322569321908
85,0.013996322569321908
deaths,0.013996322569321908
assumption,0.013874433758684055
terminated,0.013874433758684055
computing,0.013874433758684055
h1,0.013874433758684055
resulting,0.013874433758684055
intercept,0.013874433758684055
posteriori,0.013874433758684055
qualitative,0.013874433758684055
accumulated,0.013874433758684055
81,0.013874433758684055
berry,0.013874433758684055
1999,0.013874433758684055
window,0.013874433758684055
causal,0.013874433758684055
family,0.013787904226215621
monitoring,0.013787904226215621
hospital,0.013787904226215621
et,0.013787904226215621
ensure,0.013787904226215621
cause,0.013787904226215621
testing,0.013787904226215621
selection,0.013787904226215621
consent,0.013787904226215621
hospitalization,0.013787904226215621
low,0.013787904226215621
costs,0.013787904226215621
platelets,0.012389159984676795
final,0.012389159984676795
functions,0.012389159984676795
judgment,0.012389159984676795
lower,0.012389159984676795
known,0.012389159984676795
relative,0.012389159984676795
m1,0.012389159984676795
cohorts,0.012389159984676795
directly,0.012389159984676795
weight,0.012389159984676795
toxicities,0.012389159984676795
class,0.012389159984676795
adapted,0.01231655696841288
doses,0.01231655696841288
assessment,0.01231655696841288
60,0.01231655696841288
health,0.01231655696841288
decision,0.01231655696841288
70,0.01231655696841288
date,0.01231655696841288
lesions,0.01231655696841288
variables,0.011972497951224185
close,0.011972497951224185
settings,0.011972497951224185
censoring,0.011972497951224185
vaccine,0.011972497951224185
validity,0.011972497951224185
ps,0.011972497951224185
regardless,0.011972497951224185
conclusions,0.011972497951224185
2018,0.011972497951224185
controlling,0.011972497951224185
precluding,0.011972497951224185
preferred,0.011972497951224185
sum,0.011972497951224185
dropping,0.011972497951224185
2006,0.011972497951224185
truncation,0.011972497951224185
benefits,0.011972497951224185
sizes,0.011972497951224185
incorporating,0.011972497951224185
different,0.011030323380972496
central,0.011030323380972496
pr,0.011030323380972496
decrease,0.011030323380972496
allow,0.011030323380972496
major,0.011030323380972496
msc,0.011030323380972496
perform,0.011030323380972496
adalimumab,0.011030323380972496
exposed,0.011030323380972496
transfusion,0.011030323380972496
start,0.011030323380972496
tocilizumab,0.011030323380972496
beneficial,0.010497241926991432
rule,0.010497241926991432
recruited,0.010497241926991432
length,0.010497241926991432
description,0.010497241926991432
2011,0.010497241926991432
2017,0.010497241926991432
graaph,0.010497241926991432
numbers,0.010497241926991432
actg,0.010497241926991432
minimum,0.010497241926991432
diagnosis,0.010497241926991432
approximately,0.010497241926991432
stratified,0.010497241926991432
hr,0.010497241926991432
basis,0.010497241926991432
m9,0.010497241926991432
affect,0.010497241926991432
d60,0.010497241926991432
enroll,0.010497241926991432
period,0.009853245574730305
multiple,0.009853245574730305
weeks,0.009853245574730305
eye,0.009853245574730305
life,0.009853245574730305
severe,0.009853245574730305
available,0.009853245574730305
chronic,0.009853245574730305
method,0.009291869988507595
aims,0.009291869988507595
65,0.009291869988507595
21,0.009291869988507595
possible,0.009291869988507595
adaptive,0.009291869988507595
provide,0.009291869988507595
ph,0.009291869988507595
act,0.009291869988507595
stay,0.009291869988507595
ref,0.009291869988507595
reconstitution,0.009291869988507595
comparing,0.009291869988507595
effective,0.009291869988507595
target,0.009291869988507595
occurring,0.009291869988507595
objective,0.009291869988507595
receive,0.009291869988507595
bmt,0.009291869988507595
absolute,0.009291869988507595
al,0.009291869988507595
weighting,0.00924962250578937
decide,0.00924962250578937
fishers,0.00924962250578937
presents,0.00924962250578937
rejected,0.00924962250578937
remaining,0.00924962250578937
request,0.00924962250578937
requested,0.00924962250578937
biased,0.00924962250578937
distributed,0.00924962250578937
dsi,0.00924962250578937
fictive,0.00924962250578937
yes,0.00924962250578937
chained,0.00924962250578937
demonstration,0.00924962250578937
prob,0.00924962250578937
mid,0.00924962250578937
10000,0.00924962250578937
waiting,0.00924962250578937
zhou,0.00924962250578937
assumptions,0.00924962250578937
ivanova,0.00924962250578937
invest,0.00924962250578937
descriptive,0.00924962250578937
indicate,0.00924962250578937
imbalances,0.00924962250578937
sharma,0.00924962250578937
comparisons,0.00924962250578937
loghr,0.00924962250578937
accrued,0.00924962250578937
margin,0.00924962250578937
9th,0.00924962250578937
retrospectively,0.00924962250578937
suited,0.00924962250578937
inflation,0.00924962250578937
petersen,0.00924962250578937
successively,0.00924962250578937
inefficacious,0.00924962250578937
additionally,0.00924962250578937
begin,0.00924962250578937
detect,0.00924962250578937
48,0.008272742535729372
report,0.008272742535729372
care,0.008272742535729372
nk,0.008272742535729372
cycles,0.008272742535729372
measure,0.008272742535729372
aiec,0.008272742535729372
term,0.008272742535729372
single,0.008272742535729372
uninjected,0.008272742535729372
regulatory,0.008272742535729372
effects,0.008272742535729372
neutrophils,0.008272742535729372
organ,0.008272742535729372
exposure,0.008272742535729372
https,0.008272742535729372
stem,0.008272742535729372
laboratory,0.008272742535729372
outcomes,0.008272742535729372
2016,0.008272742535729372
function,0.008272742535729372
withdrawal,0.008272742535729372
2012,0.008272742535729372
prednisone,0.008272742535729372
poorly,0.007981665300816124
variable,0.007981665300816124
primarily,0.007981665300816124
populations,0.007981665300816124
worthy,0.007981665300816124
courses,0.007981665300816124
critical,0.007981665300816124
randomisation,0.007981665300816124
inefficacy,0.007981665300816124
intention,0.007981665300816124
equation,0.007981665300816124
subgroup,0.007981665300816124
37,0.007981665300816124
2010,0.007981665300816124
finite,0.007981665300816124
wang,0.007981665300816124
york,0.007981665300816124
address,0.007981665300816124
confounding,0.007981665300816124
external,0.007981665300816124
ctae,0.007981665300816124
anticipated,0.007981665300816124
med,0.007981665300816124
true,0.007981665300816124
greatly,0.007981665300816124
secondly,0.007981665300816124
consultations,0.007981665300816124
multicenter,0.007981665300816124
density,0.007981665300816124
financial,0.007981665300816124
grading,0.007981665300816124
finally,0.007981665300816124
bn,0.007981665300816124
94,0.007981665300816124
detecting,0.007981665300816124
hope,0.007981665300816124
uniform,0.007981665300816124
termination,0.007981665300816124
lee,0.007981665300816124
percent,0.007981665300816124
handling,0.007981665300816124
spending,0.007981665300816124
clin,0.007981665300816124
particularly,0.007981665300816124
investment,0.007981665300816124
interpreted,0.007981665300816124
introducing,0.007981665300816124
analyzing,0.007981665300816124
inactivity,0.007981665300816124
cells,0.007389934181047728
year,0.007389934181047728
amplification,0.007389934181047728
met,0.007389934181047728
reported,0.007389934181047728
steroids,0.007389934181047728
therapy,0.007389934181047728
order,0.007389934181047728
capmatinib,0.007389934181047728
behcets,0.007389934181047728
mg,0.007389934181047728
outcome,0.007389934181047728
anti,0.007389934181047728
50,0.007389934181047728
hsct,0.007389934181047728
rates,0.007389934181047728
40,0.007389934181047728
involve,0.006998161284660954
v3,0.006998161284660954
eradication,0.006998161284660954
subgroups,0.006998161284660954
appears,0.006998161284660954
gammaglobulin,0.006998161284660954
decided,0.006998161284660954
updated,0.006998161284660954
2015,0.006998161284660954
outside,0.006998161284660954
subcutaneously,0.006998161284660954
questionnaire,0.006998161284660954
eortc,0.006998161284660954
replaced,0.006998161284660954
reporting,0.006998161284660954
controls,0.006998161284660954
microns,0.006998161284660954
excluded,0.006998161284660954
molecular,0.006998161284660954
ferritin,0.006998161284660954
chose,0.006998161284660954
c30,0.006998161284660954
responding,0.006998161284660954
enrollment,0.006998161284660954
correlation,0.006998161284660954
admission,0.006998161284660954
comparative,0.006998161284660954
oct,0.006998161284660954
alternative,0.006998161284660954
large,0.006998161284660954
independently,0.006998161284660954
details,0.006998161284660954
died,0.006998161284660954
requirements,0.006998161284660954
immunization,0.006998161284660954
purpose,0.006998161284660954
tolerability,0.006998161284660954
limit,0.006998161284660954
conclusion,0.006998161284660954
cmv,0.006998161284660954
version,0.006194579992338398
practice,0.006194579992338398
beginning,0.006194579992338398
300,0.006194579992338398
cr,0.006194579992338398
versus,0.006194579992338398
positive,0.006194579992338398
2003,0.006194579992338398
chosen,0.006194579992338398
ebv,0.006194579992338398
respond,0.006194579992338398
donors,0.006194579992338398
erythrocyte,0.006194579992338398
allowing,0.006194579992338398
22,0.006194579992338398
pfs,0.006194579992338398
os,0.006194579992338398
occurs,0.006194579992338398
common,0.006194579992338398
note,0.006194579992338398
account,0.006194579992338398
consecutive,0.006194579992338398
age,0.006194579992338398
2008,0.006194579992338398
shown,0.006194579992338398
developed,0.006194579992338398
coherence,0.006194579992338398
allows,0.006194579992338398
association,0.006194579992338398
optical,0.006194579992338398
uncontrolled,0.006194579992338398
underlying,0.006194579992338398
presence,0.005515161690486248
present,0.005515161690486248
visit,0.005515161690486248
follows,0.005515161690486248
33,0.005515161690486248
36,0.005515161690486248
injected,0.005515161690486248
bd,0.005515161690486248
sun,0.005515161690486248
subject,0.005515161690486248
usual,0.005515161690486248
partial,0.005515161690486248
tolerance,0.005515161690486248
concerning,0.005515161690486248
engraftment,0.005515161690486248
louis,0.005515161690486248
red,0.005515161690486248
reduce,0.005515161690486248
ks,0.005515161690486248
sparing,0.005515161690486248
starting,0.005515161690486248
place,0.005515161690486248
plan,0.005515161690486248
interaction,0.005515161690486248
terms,0.005515161690486248
higher,0.005515161690486248
haze,0.005515161690486248
line,0.005515161690486248
loss,0.005515161690486248
appropriate,0.005515161690486248
graft,0.005515161690486248
55,0.005515161690486248
belimumab,0.005515161690486248
transfusions,0.005515161690486248
mortality,0.005515161690486248
visual,0.005515161690486248
18,0.005515161690486248
11,0.005515161690486248
17,0.005515161690486248
vasculitis,0.0049266227873651525
vitreous,0.0049266227873651525
medical,0.0049266227873651525
donor,0.0049266227873651525
resolution,0.0049266227873651525
macular,0.0049266227873651525
refractory,0.0049266227873651525
ongoing,0.0049266227873651525
complications,0.0049266227873651525
iv,0.0049266227873651525
second,0.0049266227873651525
independent,0.0049266227873651525
step,0.0049266227873651525
placebo,0.0049266227873651525
hematopoietic,0.0049266227873651525
associated,0.0049266227873651525
evidence,0.0049266227873651525
failure,0.0049266227873651525
pre,0.0049266227873651525
chimerism,0.0049266227873651525
systemic,0.0049266227873651525
activity,0.0049266227873651525
peripheral,0.0049266227873651525
immune,0.0049266227873651525
infections,0.0049266227873651525
corticosteroid,0.0049266227873651525
modify,0.004624811252894685
ya,0.004624811252894685
centered,0.004624811252894685
retained,0.004624811252894685
roughly,0.004624811252894685
62,0.004624811252894685
rely,0.004624811252894685
representing,0.004624811252894685
aesi,0.004624811252894685
scales,0.004624811252894685
matthieu,0.004624811252894685
making,0.004624811252894685
admissions,0.004624811252894685
nilotinib,0.004624811252894685
obtention,0.004624811252894685
linearity,0.004624811252894685
leave,0.004624811252894685
biostatistics,0.004624811252894685
confirmatory,0.004624811252894685
enhance,0.004624811252894685
monitor,0.004624811252894685
multiplicity,0.004624811252894685
na,0.004624811252894685
economic,0.004624811252894685
residuals,0.004624811252894685
modeling,0.004624811252894685
modelling,0.004624811252894685
res,0.004624811252894685
doi,0.004624811252894685
represented,0.004624811252894685
withdrawals,0.004624811252894685
variance,0.004624811252894685
111,0.004624811252894685
fitting,0.004624811252894685
wilcoxons,0.004624811252894685
january,0.004624811252894685
jm,0.004624811252894685
spiegelhalter,0.004624811252894685
spline,0.004624811252894685
square,0.004624811252894685
sr,0.004624811252894685
csi,0.004624811252894685
simulations,0.004624811252894685
smoothing,0.004624811252894685
soon,0.004624811252894685
computation,0.004624811252894685
semi,0.004624811252894685
empirical,0.004624811252894685
electronic_applications,0.004624811252894685
enrolling,0.004624811252894685
incomplete,0.004624811252894685
subsets,0.004624811252894685
survive,0.004624811252894685
suspended,0.004624811252894685
quickly,0.004624811252894685
pooled,0.004624811252894685
protocoldevelopment,0.004624811252894685
purposes,0.004624811252894685
quantity,0.004624811252894685
coded,0.004624811252894685
collects,0.004624811252894685
add,0.004624811252894685
reach,0.004624811252894685
entered,0.004624811252894685
inverse,0.004624811252894685
amendment,0.004624811252894685
ja,0.004624811252894685
balanced,0.004624811252894685
htm,0.004624811252894685
impacts,0.004624811252894685
suspicion,0.004624811252894685
clinicians,0.004624811252894685
sylvie,0.004624811252894685
applying,0.004624811252894685
tools,0.004624811252894685
probabilities,0.004624811252894685
der,0.004624811252894685
densities,0.004624811252894685
defining,0.004624811252894685
chi,0.004624811252894685
ctep,0.004624811252894685
ctc_50,0.004624811252894685
handle,0.004624811252894685
chance,0.004624811252894685
checking,0.004624811252894685
chevret,0.004624811252894685
annals,0.004624811252894685
going,0.004624811252894685
filled,0.004624811252894685
fall,0.004624811252894685
exceed,0.004624811252894685
goes,0.004624811252894685
frequentist,0.004624811252894685
formulation,0.004624811252894685
frequencies,0.004624811252894685
price,0.004624811252894685
predictors,0.004624811252894685
06,0.004624811252894685
146,0.004624811252894685
web,0.003990832650408062
fleming,0.003990832650408062
ex,0.003990832650408062
eventually,0.003990832650408062
d15,0.003990832650408062
92,0.003990832650408062
projected,0.003990832650408062
department,0.003990832650408062
decisions,0.003990832650408062
1994,0.003990832650408062
tyndall,0.003990832650408062
transmitted,0.003990832650408062
toxic,0.003990832650408062
application,0.003990832650408062
appeared,0.003990832650408062
tomographic,0.003990832650408062
titers,0.003990832650408062
implies,0.003990832650408062
immunosuppressives,0.003990832650408062
accrual,0.003990832650408062
accounting,0.003990832650408062
accordingly,0.003990832650408062
d45,0.003990832650408062
subsequent,0.003990832650408062
studied,0.003990832650408062
individual,0.003990832650408062
incidences,0.003990832650408062
assessing,0.003990832650408062
esr,0.003990832650408062
escalation,0.003990832650408062
allowed,0.003990832650408062
initially,0.003990832650408062
34,0.003990832650408062
2021,0.003990832650408062
2020,0.003990832650408062
2019,0.003990832650408062
stock,0.003990832650408062
actual,0.003990832650408062
rare,0.003990832650408062
randomly,0.003990832650408062
questionaire,0.003990832650408062
published,0.003990832650408062
policy,0.003990832650408062
anakinra,0.003990832650408062
standards,0.003990832650408062
stages,0.003990832650408062
st,0.003990832650408062
lariboisiere,0.003990832650408062
larger,0.003990832650408062
kawasaki,0.003990832650408062
reappearance,0.003990832650408062
crossed,0.003990832650408062
reactive,0.003990832650408062
reactivations,0.003990832650408062
reached,0.003990832650408062
snellen,0.003990832650408062
light,0.003990832650408062
laws,0.003990832650408062
effectively,0.003990832650408062
ecrf,0.003990832650408062
lymphedema,0.003990832650408062
simon,0.003990832650408062
shows,0.003990832650408062
screened,0.003990832650408062
scored,0.003990832650408062
66,0.003990832650408062
aes,0.003990832650408062
magic,0.003990832650408062
occur,0.003990832650408062
obrien,0.003990832650408062
recoveries,0.003990832650408062
reasonable,0.003990832650408062
43,0.003990832650408062
result,0.003990832650408062
meaning,0.003990832650408062
matching,0.003990832650408062
market,0.003990832650408062
marginal,0.003990832650408062
conversely,0.003990832650408062
donnees,0.003990832650408062
mr,0.003990832650408062
nrm,0.003990832650408062
neutrophiles,0.003990832650408062
way,0.003990832650408062
units,0.003990832650408062
fewer,0.003990832650408062
extracted,0.003990832650408062
globally,0.003990832650408062
functioning,0.003990832650408062
precision,0.003990832650408062
vfq,0.003990832650408062
van,0.003990832650408062
03,0.003990832650408062
162,0.003990832650408062
world,0.003499080642330477
zero,0.003499080642330477
validate,0.003499080642330477
v4,0.003499080642330477
newly,0.003499080642330477
discharge,0.003499080642330477
optimized,0.003499080642330477
prednisolone,0.003499080642330477
features,0.003499080642330477
nb,0.003499080642330477
13,0.003499080642330477
observational,0.003499080642330477
sae,0.003499080642330477
400,0.003499080642330477
logmar,0.003499080642330477
leakage,0.003499080642330477
efs,0.003499080642330477
effectiveness,0.003499080642330477
similar,0.003499080642330477
sedimentation,0.003499080642330477
make,0.003499080642330477
mainly,0.003499080642330477
scheduled,0.003499080642330477
schedule,0.003499080642330477
54,0.003499080642330477
dfs,0.003499080642330477
records,0.003499080642330477
earlier,0.003499080642330477
allocated,0.003499080642330477
easily,0.003499080642330477
40mg,0.003499080642330477
49,0.003499080642330477
drugs,0.003499080642330477
action,0.003499080642330477
outpatient,0.003499080642330477
reaches,0.003499080642330477
platform,0.003499080642330477
clinic,0.003499080642330477
growth,0.003499080642330477
applied,0.003499080642330477
terminology,0.003499080642330477
targets,0.003499080642330477
average,0.003499080642330477
assigned,0.003499080642330477
access,0.003499080642330477
prospectively,0.003499080642330477
acceptable,0.003499080642330477
protein,0.003499080642330477
epidemiology,0.003499080642330477
independence,0.003499080642330477
ensuring,0.003499080642330477
survey,0.003499080642330477
analyze,0.003499080642330477
paraclinical,0.003499080642330477
35,0.003499080642330477
investigating,0.003499080642330477
qlq,0.003499080642330477
2005,0.003499080642330477
chelation,0.003499080642330477
120,0.003499080642330477
d29,0.003499080642330477
explored,0.003499080642330477
ctc,0.003499080642330477
des,0.003499080642330477
principal,0.003499080642330477
gov,0.003499080642330477
preexisting,0.003499080642330477
angiography,0.003499080642330477
special,0.003499080642330477
later,0.003499080642330477
stated,0.003499080642330477
organs,0.003499080642330477
reactants,0.003499080642330477
questionnaires,0.003499080642330477
american,0.003499080642330477
spontaneous,0.003499080642330477
left,0.003097289996169199
law,0.003097289996169199
endoscopic,0.003097289996169199
sibling,0.003097289996169199
saint,0.003097289996169199
repeated,0.003097289996169199
national,0.003097289996169199
relapses,0.003097289996169199
global,0.003097289996169199
formula,0.003097289996169199
potentially,0.003097289996169199
fact,0.003097289996169199
usually,0.003097289996169199
search,0.003097289996169199
80mg,0.003097289996169199
adequate,0.003097289996169199
recent,0.003097289996169199
detailed,0.003097289996169199
nei,0.003097289996169199
diseases,0.003097289996169199
replacement,0.003097289996169199
worsening,0.003097289996169199
modification,0.003097289996169199
vital,0.003097289996169199
flare,0.003097289996169199
choice,0.003097289996169199
charge,0.003097289996169199
examination,0.003097289996169199
graall,0.003097289996169199
define,0.003097289996169199
transplanted,0.003097289996169199
tomography,0.003097289996169199
implemented,0.003097289996169199
impact,0.003097289996169199
immediate,0.003097289996169199
imaging,0.003097289996169199
collect,0.003097289996169199
tolerated,0.003097289996169199
taking,0.003097289996169199
decreased,0.003097289996169199
pathology,0.003097289996169199
protection,0.003097289996169199
proposed,0.003097289996169199
addition,0.003097289996169199
overlap,0.003097289996169199
indexed,0.003097289996169199
evaluate,0.003097289996169199
hopital,0.003097289996169199
bcva,0.003097289996169199
qol,0.003097289996169199
acuity,0.003097289996169199
provided,0.003097289996169199
crp,0.003097289996169199
composite,0.003097289996169199
participants,0.003097289996169199
complementary,0.003097289996169199
binding,0.003097289996169199
lymphocyte,0.003097289996169199
meeting,0.003097289996169199
continue,0.003097289996169199
measurement,0.003097289996169199
recommendation,0.003097289996169199
corrected,0.003097289996169199
meet,0.003097289996169199
combined,0.003097289996169199
ctcae,0.003097289996169199
gamma,0.003097289996169199
2013,0.002757580845243124
visits,0.002757580845243124
biopsies,0.002757580845243124
significant,0.002757580845243124
limited,0.002757580845243124
recommended,0.002757580845243124
medications,0.002757580845243124
manifestations,0.002757580845243124
m2,0.002757580845243124
camostat,0.002757580845243124
residual,0.002757580845243124
cancer,0.002757580845243124
matched,0.002757580845243124
mixed,0.002757580845243124
onset,0.002757580845243124
obtain,0.002757580845243124
concomitant,0.002757580845243124
reduction,0.002757580845243124
receiving,0.002757580845243124
reference,0.002757580845243124
eligibility,0.002757580845243124
flow,0.002757580845243124
centre,0.002757580845243124
chamber,0.002757580845243124
good,0.002757580845243124
change,0.002757580845243124
appendix,0.002757580845243124
antibody,0.002757580845243124
taken,0.002757580845243124
ileal,0.002757580845243124
collected,0.002757580845243124
classification,0.002757580845243124
assess,0.002757580845243124
hospitalizations,0.002757580845243124
syndromes,0.002757580845243124
having,0.002757580845243124
unit,0.002757580845243124
status,0.002757580845243124
specified,0.002757580845243124
late,0.002757580845243124
isatuximab,0.002757580845243124
long,0.002757580845243124
committee,0.002757580845243124
paris,0.002757580845243124
cov2,0.002757580845243124
able,0.002757580845243124
support,0.002757580845243124
infectious,0.002757580845243124
platelet,0.002757580845243124
surgery,0.002757580845243124
identical,0.002757580845243124
benefit,0.0024633113936825763
followed,0.0024633113936825763
signs,0.0024633113936825763
edema,0.0024633113936825763
sars,0.0024633113936825763
conditioning,0.0024633113936825763
management,0.0024633113936825763
ocular,0.0024633113936825763
cardiac,0.0024633113936825763
modified,0.0024633113936825763
unrelated,0.0024633113936825763
vessel,0.0024633113936825763
prca,0.0024633113936825763
cryoglobulinemia,0.0024633113936825763
active,0.0024633113936825763
steroid,0.0024633113936825763
involvement,0.0024633113936825763
poor,0.0024633113936825763
plasma,0.0024633113936825763
daily,0.0024633113936825763
increased,0.0024633113936825763
infection,0.0024633113936825763
injection,0.0024633113936825763
syndrome,0.0024633113936825763
haplo,0.0024633113936825763
high,0.0024633113936825763
tnf,0.0024633113936825763
collection,0.0024633113936825763
19,0.0024633113936825763
previously,0.0024633113936825763
procedure,0.0024633113936825763
anterior,0.0024633113936825763
evolution,0.0024633113936825763
current,0.0024633113936825763
